AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.17 which represents a decrease of $-3.33 or -1.87% from the prior close of $178.5. The stock opened at $176.86 and touched a low of ...

Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected ...

AbbVie (NYSE:ABBV) and AbCellera (NASDAQ:ABCL) have expanded their collaboration to include the discovery of T-cell engagers for the treatment of cancer. Under the deal, AbCellera (NASDAQ:ABCL) will ...

The technology industry is well-positioned for significant growth thanks to the rapid advancements in emerging technologies ...

AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., entered an option to license agreement to develop SIM0500, an investigational new drug candidate in Phase 1 trials in ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th ...